MG-K10 Phase 3 Trial for Chronic Spontaneous Urticaria, NCT07546487
Summary
A new Phase 3 clinical trial for MG-K10 humanized monoclonal antibody injection has been registered on ClinicalTrials.gov under NCT07546487. The multicenter, randomized, double-blind, placebo-controlled study will evaluate efficacy and safety in approximately 300 adult participants with Chronic Spontaneous Urticaria inadequately controlled by second-generation H1 antihistamines. Participants will receive either MG-K10 or placebo via subcutaneous injection.
“This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial aimed at evaluating the efficacy and safety of MG-K10 humanized monoclonal antibody injection in CSU trial participants with poor control of second-generation H1 antihistamines.”
About this source
GovPing monitors ClinicalTrials.gov Studies for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 667 changes logged to date.
What changed
A new Phase 3 clinical trial (NCT07546487) evaluating MG-K10 humanized monoclonal antibody injection has been registered on ClinicalTrials.gov. The study is a multicenter, randomized, double-blind, placebo-controlled trial enrolling approximately 300 adult participants with Chronic Spontaneous Urticaria who have inadequate control on second-generation H1 antihistamines. The primary purpose is to evaluate efficacy and safety of MG-K10 versus placebo.
Pharmaceutical companies and clinical investigators involved in immunology or dermatology drug development should note this entry in the clinical trial pipeline. Sponsors developing competing CSU therapies may find this relevant for competitive landscape monitoring and trial design considerations.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Study of MG-K10 in Chronic Spontaneous Urticaria
Phase 3 NCT07546487 Kind: PHASE3 Apr 22, 2026
Abstract
This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial aimed at evaluating the efficacy and safety of MG-K10 humanized monoclonal antibody injection in CSU trial participants with poor control of second-generation H1 antihistamines.
Conditions: Chronic Spontaneous Urticaria (CSU)
Interventions: MG-K10 Humanized Monoclonal Antibody Injection, Placebo
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.